tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kim EJ et al. | Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. | 2014 | Am. J. Transplant. | pmid:24354871 |
| Frassetto LA et al. | Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17949460 |
| Cosio FG and Larson TS | Cardiovascular disease after transplantation: do we know all of the variables? | 2003 | Am. J. Transplant. | pmid:12859523 |
| Krämer BK et al. | Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. | 2003 | Am. J. Transplant. | pmid:12859533 |
| Xu H et al. | The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. | 2014 | Am. J. Transplant. | pmid:24472192 |
| Coghill AE et al. | Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. | 2016 | Am. J. Transplant. | pmid:26824445 |
| Ekberg H et al. | Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | 2009 | Am. J. Transplant. | pmid:19563339 |
| Mehra MR et al. | Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. | 2006 | Am. J. Transplant. | pmid:16686745 |
| Grimm M et al. | Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. | 2006 | Am. J. Transplant. | pmid:16686762 |
| Sis B et al. | Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. | 2006 | Am. J. Transplant. | pmid:16686769 |
| Duncan FJ et al. | Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. | 2007 | Am. J. Transplant. | pmid:17941958 |
| Hu X et al. | Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. | 2016 | Am. J. Transplant. | pmid:26749344 |
| Cameron AM et al. | Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine. | 2016 | Am. J. Transplant. | pmid:26748958 |
| Bouamar R et al. | Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). | 2013 | Am. J. Transplant. | pmid:23480233 |
| Busque S et al. | The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. | 2011 | Am. J. Transplant. | pmid:21943027 |
| Kaufman DB et al. | Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. | 2005 | Am. J. Transplant. | pmid:16162205 |
| Naesens M et al. | Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. | 2007 | Am. J. Transplant. | pmid:17608835 |
| Schwarz A et al. | Polyoma virus nephropathy in native kidneys after lung transplantation. | 2005 | Am. J. Transplant. | pmid:16162212 |
| Shemesh E et al. | The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. | 2017 | Am. J. Transplant. | pmid:28321975 |
| Van Laecke S et al. | Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. | 2009 | Am. J. Transplant. | pmid:19624560 |
| Heisel O et al. | New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. | 2004 | Am. J. Transplant. | pmid:15023151 |
| Hardinger KL et al. | Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. | 2004 | Am. J. Transplant. | pmid:15023155 |
| Suwelack B et al. | Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. | 2004 | Am. J. Transplant. | pmid:15023160 |
| Pescovitz MD et al. | A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19663892 |
| Bryan CF et al. | Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. | 2007 | Am. J. Transplant. | pmid:17359511 |
| Diaz-Siso JR et al. | Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. | 2015 | Am. J. Transplant. | pmid:25777324 |
| Rodriguez-Rodriguez AE et al. | The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. | 2013 | Am. J. Transplant. | pmid:23651473 |
| Klintmalm GB et al. | Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. | 2014 | Am. J. Transplant. | pmid:25041339 |
| Jaksch P et al. | Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. | 2014 | Am. J. Transplant. | pmid:25039364 |
| Neuberger JM et al. | Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. | 2009 | Am. J. Transplant. | pmid:19120077 |
| Momper JD et al. | The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. | 2011 | Am. J. Transplant. | pmid:21714845 |
| TruneÄŒka P et al. | Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. | 2015 | Am. J. Transplant. | pmid:25707487 |
| Adam R et al. | Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. | 2015 | Am. J. Transplant. | pmid:25703527 |
| Asrani SK and O'Leary JG | Can one pill a day keep rejection away? | 2015 | Am. J. Transplant. | pmid:25703394 |
| Oetting WS et al. | Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. | 2016 | Am. J. Transplant. | pmid:26485092 |
| Badri P et al. | Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. | 2015 | Am. J. Transplant. | pmid:25708713 |
| Vitko S et al. | Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. | 2006 | Am. J. Transplant. | pmid:16468962 |
| Carenco C et al. | Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. | 2015 | Am. J. Transplant. | pmid:25648361 |
| Mulay AV et al. | Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. | 2009 | Am. J. Transplant. | pmid:19353768 |
| Bourdeaux C et al. | Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. | 2007 | Am. J. Transplant. | pmid:17173657 |
| Heller T et al. | Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. | 2007 | Am. J. Transplant. | pmid:17532750 |
| Schrepfer S et al. | Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. | 2007 | Am. J. Transplant. | pmid:17532751 |
| Rostaing L et al. | Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23730730 |
| Grinyo JM et al. | Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15268733 |
| Posselt AM et al. | Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. | 2010 | Am. J. Transplant. | pmid:20659093 |
| Jacobson PA et al. | Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. | 2012 | Am. J. Transplant. | pmid:22947444 |
| De Simone P et al. | Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. | 2012 | Am. J. Transplant. | pmid:22882750 |
| Echeverri GJ et al. | Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. | 2009 | Am. J. Transplant. | pmid:19775318 |
| Gaston RS et al. | Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. | 2009 | Am. J. Transplant. | pmid:19459794 |
| Lake JR et al. | Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. | 2005 | Am. J. Transplant. | pmid:16303011 |